(Total Views: 432)
Posted On: 08/22/2019 5:21:28 PM
Post# of 156758
Capsid Inhibitors .
We talked about it few times ,
They did phase 1 study with HIV negative patients , to evaluate safety and concentration level.
40 patients double-blind study. 4 groups of patients on different dose , 30, 100, 300 and 450 mg.
Patients on lower dose stay up to 20 wks , patients on higher dose for 4 weeks.
So far no serious side effects but probably to soon to know in humans.
Now phase 1 B , hoping to finish sometimes during second part of 2020 , with HIV positive patients , so as nice as it sound lets see how HIV positive patients will respond.
they will have 64 patients , double-blinded , some patients will be compare to placebo and some to Tenofovir.
It will be a long rd from here , but early study in vitro promising ...
We talked about it few times ,
They did phase 1 study with HIV negative patients , to evaluate safety and concentration level.
40 patients double-blind study. 4 groups of patients on different dose , 30, 100, 300 and 450 mg.
Patients on lower dose stay up to 20 wks , patients on higher dose for 4 weeks.
So far no serious side effects but probably to soon to know in humans.
Now phase 1 B , hoping to finish sometimes during second part of 2020 , with HIV positive patients , so as nice as it sound lets see how HIV positive patients will respond.
they will have 64 patients , double-blinded , some patients will be compare to placebo and some to Tenofovir.
It will be a long rd from here , but early study in vitro promising ...
(1)
(0)
